kwic
further
further
right
off
ON
172
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for further out of >500 occurrences
298283 occurrences (No.79 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to further]
298283 occurrences (No.79 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 172) The mean improvement in total passive extension deficit (TPED) was 34° on day 1, improving further by day 7 to 42°. |
| PMID:24470559 DOI:10.1177/1753193413519926 |
| 2015 The Journal of hand surgery, European volume |
| * Collagenase clostridium histolyticum in patients with Dupuytren's contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. |
| - In POINT X, a study designed to reflect clinical practice and patient treatment choices, 254 European patients received open-label collagenase for Dupuytren's contracture. The most severely affected joint was treated first in 74% of patients. In total, 52%, 41%, 7%, and 1% of patients selected the little, ring, middle, and index finger, respectively; 79% had one or two joints treated. Only 9% of patients (n = 24) received 4 or 5 injections. The mean improvement in total passive extension deficit (TPED) was 34° on day 1, improving further by day 7 to 42°. This secondary improvement was maintained by day 90 and month 6. The mean number of injections/joint was 1.2 for the metacarpophalangeal joint and 1.25 for the proximal interphalangeal joint. Median time to recovery was 4 days; the mean improvement in hand function was clinically relevant as measured by the Unité Rhumatologique des Affections de la Main (URAM) score. In total, 87% and 86% of patients and physicians, respectively, were very satisfied or satisfied with treatment at month 6, although correlation between TPED and patient satisfaction was weak (Spearman -0.18, 95% CI -0.32 to -0.06). Collagenase was well tolerated, with 10 (3.9%) patients experiencing severe adverse events. As a real-world study, the POINT X findings can be generalized to the at-large population. |
[
right
kwic]
(1)39  studies |
(16)4 developed |
(31)2 analyses |
(46)2 insights |
| (2)32 research |
(17)4 in |
(32)2 analyzed |
(47)2 monitoring |
| (3)18 investigation |
(18)4 supported |
(33)2 application |
(48)2 optimization |
| (4)18 study |
(19)3 *null* | (34)2 as |
(49)2 prospective |
| (5)11 the |
(20)3 a |
(35)2 assessed |
(50)2 protection |
| (6)10 investigations |
(21)3 clinical |
(36)2 complications |
(51)2 spread |
| (7)8 analysis |
(22)3 evaluation |
(37)2 divided |
(52)2 suggests |
| (8)7 evidence |
(23)3 exploration |
(38)2 elucidate |
(53)2 supporting |
| (9)7 phylogenetic |
(24)3 explore |
(39)2 enhance |
(54)2 supports |
| (10)6 explored |
(25)3 for |
(40)2 episodes |
(55)2 taxonomic |
| (11)5 development |
(26)3 increased |
(41)2 evaluated |
(56)2 that |
| (12)5 support |
(27)3 investigate |
(42)2 examination |
(57)2 used |
| (13)5 validation |
(28)3 molecular |
(43)2 identification |
|
| (14)4 by |
(29)3 understand |
(44)2 improvement |
|
| (15)4 confirmed |
(30)2 advances |
(45)2 increase |
add keyword
--- WordNet output for further ---